Akèy › Kansè san › Kalifòni › Los Angeles
Etid klinik pou Kansè san nan Los Angeles, CA
17 etid pou Kansè san ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Ap rekriteFaz 3
- UCLA - Hematology/Oncology - Administrative Office ( Site 0009), Los Angeles
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 7, Los Angeles
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- UCLA Medical Center, Los Angeles
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles, Los Angeles
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Health - Bowyer Oncology Center, Los Angeles
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Ap rekriteFaz 1
- University of California, Los Angeles
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Ap rekriteFaz 1
- Cedars-Sinai Medical Center, Los Angeles
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
Ap rekriteFaz 1
- Cedars-Sinai Medical Center, Los Angeles
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ap rekriteFaz 1
- START Los Angele, Los Angeles
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- UCLA Department of Medicine, Los Angeles
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- UCLA, Los Angeles
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Ap rekriteFaz 3
- University of California LA, Los Angeles
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- USC / Norris Comprehensive Cancer Center, Los Angeles
- UCLA - Bowyer Oncology Center, Los Angeles
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Ap rekriteEtid obsèvasyon
- University of Southern California - Norris Comprehensive Cancer Center, Los Angeles
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Ap rekriteFaz 1/2
- Valkyrie Clinical Trials, Los Angeles
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Children's Hospital Los Angeles, Los Angeles
Etid Kansè san nan lòt vil
- Houston, TX46 etid
- New York City, NY26 etid
- Boston, MA25 etid
- Washington, DC19 etid
- Seattle, WA18 etid
- Baltimore, MD18 etid
- Durham, NC16 etid
- Chicago, IL15 etid
- Philadelphia, PA14 etid
- Nashville, TN13 etid
- Columbus, OH13 etid
- Edison, NJ13 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)74 etid
- Kansè nan tete73 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.